Boosting natural brain opioids may be a better way to treat anxiety, according to a recent study.
The University of Sydney findings suggest medications that boost the effect of natural brain opioids might be a better way to reduce anxiety than 'receptor-binding' opioid drugs like morphine, which have major side effects.
Anxiety disorders affect 14 per cent of Australians but are poorly managed by commonly prescribed medications such as benzodiazepines and 5HT-reuptake inhibitors.
"These drugs weren't developed to treat anxiety but they're widely used because of chance findings suggesting their clinical usefulness," said lead author Elena Bagley, adding "Many experts agree that better anxiety treatments will come when science uncovers how the neural circuits and endogenous or naturally occurring opioids regulate fear and anxiety."
"The precise action of these natural opioids in the brain is poorly understood, but better insights are critical because these opiods control how we acquire and store fear memories and regulate our emotional responses once a threat has passed," she added.
Experiments in mice have shown that 'deleting' the natural opioid enkephalin, which is heavily expressed in the brain's amygdala, increases their fear, anxiety and aggressiveness. By contrast, increasing enkephalin or reducing its breakdown reduces these behaviours.
While this effect of enkephalin suggests that it is anxiety-inhibiting, when it binds to different receptors in the amygdala, it exerts opposing effects, depending on which one it binds to.
For example, when it binds to the mu-opioid receptor, enkephalin promotes anxiety, but when it binds to the delta-opioid receptor, it inhibits it.
"Given this complexity, understanding the cellular actions of natural opioids at these two receptors is critical if we hope to use opioid-related medications for emotional issues," said Dr Bagley.
"Our findings show that opioids produced and released by our own brain cells strongly regulate these critical neural circuits that are important for fear responses. We also show that we could boost the actions of these endogenous opioids using a novel pharmacological approach," she noted.
The study is published in Nature Communications.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
